Preclinical and clinical studies have shown that TGF-β reduces the efficacy of CAR T cell therapy in solid tumors and hematological malignancies by suppressing T cell proliferation, cytokine production, and cytolytic activity.2,17,21,37,38 In contrast, our TGF-βRII CAR design successfully overcomes this limitation, a feature that is not observed in the designed dnTβRII T cells. Here, TGFB1 is linked to hematologic disorder.